---
title: "Sinolink Securities Keeps Their Buy Rating on Simcere Pharmaceutical Group Limited (2096)"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/269667021.md"
description: "Sinolink Securities maintains a Buy rating on Simcere Pharmaceutical Group Limited with a price target of HK$20.16. The general analyst consensus is a Moderate Buy with an average price target of HK$17.75."
datetime: "2025-12-15T05:05:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/269667021.md)
  - [en](https://longbridge.com/en/news/269667021.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/269667021.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/269667021.md) | [繁體中文](https://longbridge.com/zh-HK/news/269667021.md)


# Sinolink Securities Keeps Their Buy Rating on Simcere Pharmaceutical Group Limited (2096)

Sinolink Securities analyst maintained a Buy rating on Simcere Pharmaceutical Group Limited yesterday and set a price target of HK$20.16.

### Claim 50% Off TipRanks Premium and Invest with Confidence

-   Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Simcere Pharmaceutical Group Limited with a HK$17.75 average price target.

### 相关股票

- [SIMCERE PHARMA (02096.HK)](https://longbridge.com/zh-CN/quote/02096.HK.md)

## 相关资讯与研究

- [Simcere Pharmaceutical Group Limited (2096) Receives a Buy from Bank of China](https://longbridge.com/zh-CN/news/281137424.md)
- [Simcere Pharmaceutical Presents Bladder Cancer Drug Trial Results at European Urology Conference](https://longbridge.com/zh-CN/news/279439171.md)
- [Longfor Group Holdings (LNGPF) Gets a Buy from CICC](https://longbridge.com/zh-CN/news/280899756.md)
- [Huatai Securities Sticks to Their Buy Rating for Simcere Pharmaceutical Group Limited (2096)](https://longbridge.com/zh-CN/news/270691523.md)
- [Sinolink Securities Sticks to Its Buy Rating for Simcere Pharmaceutical Group Limited (2096)](https://longbridge.com/zh-CN/news/270967374.md)